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Molecular Profiling of Decompensated 
Cirrhosis by a Novel MicroRNA Signature
Ana Garcia Garcia de Paredes ,1* Nicolo Manicardi ,2* Luis Tellez ,1,3* Luis Ibañez ,3,4 Felix Royo,3,5 Javier Bermejo,6 
Carolina Blanco ,7 Constantino Fondevila,3,8 Val Fernandez Lanza,9 Laura Garcia-Bermejo ,7 Juan Manuel Falcon-Perez,3,5,10 
Rafael Bañares ,3,4 Jordi Gracia-Sancho ,2,3** and Agustin Albillos 1,3**
Noninvasive staging of decompensated cirrhosis is an unmet clinical need. The aims of this study were to characterize 
and validate a novel microRNA (miRNA) signature to stage decompensated cirrhosis and predict the portal pressure 
and systolic cardiac response to nonselective beta-blockers (NSBBs). Serum samples from patients with decompensated 
cirrhosis (n  =  36) and healthy controls (n  =  36) were tested for a novel signature of five miRNAs (miR-452-5p, miR-
429, miR-885-5p, miR-181b-5p, and miR-122-5p) identified in the secretome of primary human hepatocytes and for 
three miRNAs (miR-192-5p, miR-34a-5p, and miR-29a-5p) previously discovered as biomarkers of chronic liver disease. 
All patients had ascites, which was refractory in 18 (50%), and were placed on NSBBs for variceal bleeding prophylaxis. 
In all patients, serum miRNAs, hepatic venous pressure gradient, and an echocardiogram study were performed before 
and 1  month after NSBBs. Patients with cirrhosis had lower serum levels of miR-429, miR-885-5p, miR-181b-5p, 
miR-122-5p, miR-192-5p, and miR-29a-5p (P  <  0.05). Baseline serum miR-452-5p and miR-429 levels were lower in 
NSBB responders (P  =  0.006). miR-181b-5p levels were greater in refractory ascites than in diuretic-sensitive ascites 
(P  =  0.008) and correlated with serum creatinine. miR-452-5p and miR-885-5p were inversely correlated with baseline 
systemic vascular resistance (ρ  =  −0.46, P  =  0.007; and ρ  =  −0.41, P  =  0.01, respectively) and with diminished systolic 
contractility (ρ  =  −0.55, P  =  0.02; and ρ  =  −0.55, P  =  0.02, respectively) in patients with refractory ascites after NSBBs. 
Conclusion: Analysis of a miRNA signature in serum discriminates between patients with decompensated cirrhosis who 
show more severe systemic circulatory dysfunction and compromised systolic function after beta-blockade and those 
more likely to benefit from NSBBs. (Hepatology Communications 2021;5:309-322).
MicroRNAs (miRNAs) are small noncod-ing RNA molecules (18-25 nucleotides) involved in the posttranscriptional regu-
lation of protein-coding genes controlling many cel-
lular processes.(1) In serum, miRNAs may be bound 
to circulating proteins or, more frequently, contained 
within extracellular vesicles (EVs).(2) EVs are nano-
metric double-membrane structures that envelop miR-
NAs and shuttle this biological information from one 
cell type to another. Because their cargo dynamically 
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microRNA; NSBB, nonselective beta-blocker; PCR, polymerase chain reaction; qRT-PCR, quantitative reverse-transcription polymerase chain 
reaction; vol, volume; XIAP, X-linked inhibitor of apoptosis protein.
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changes depending on different physiopathological 
stimuli, it has been hypothesized that EVs themselves 
and/or EV-housed miRNAs may serve as noninvasive 
biomarkers to assess disease course, progression, and 
therapeutic response.(3)
Cirrhosis is a progressive disease that develops over 
two consecutive stages, compensated and decom-
pensated, each with different clinical characteristics 
and prognoses.(4) Within the decompensated stage, 
further decompensation leads to refractory ascites, a 
stage of cirrhosis characterized by severe peripheral 
vasodilation, reduced cardiac reserve, and a dismal 
prognosis.(5-7) For patients with cirrhosis, nonselective 
beta-blockers (NSBBs) are the cornerstone treatment 
to prevent first and recurrent variceal bleeding.(8) 
The response to NSBBs, as defined by a reduction 
in the hepatic venous pressure gradient (HVPG) ≥ 
10%, has been associated with reduced variceal 
bleeding and ascites development and increased sur-
vival.(9-12) However, the beneficial effects of NSBBs 
may not extend to the whole population of patients 
with decompensated cirrhosis. In fact, NSBBs may 
be harmful in patients with refractory ascites as they 
may compromise their cardiac compensatory reserve 
with the consequences of insufficient cardiac output 
and renal failure.(7,13) Clinicians, therefore, need to be 
cautious about prescribing NSBBs to these patients 
with refractory ascites. There is a lack of noninva-
sive biomarkers to identify patients with decompen-
sated cirrhosis more prone to develop complications. 
Personalized molecular profiling could be useful to 
identify those subjects with severe circulatory dys-
function in which NSBBs may be risky.
This study was designed to examine the correla-
tion of a novel serum miRNA signature with several 
outcomes in decompensated cirrhosis. This signature 
was identified according to its differential expression 
in EVs in the secretome of hepatocytes from livers 
of patients with cirrhosis. Our working hypothesis 
was that the proposed miRNA signature would likely 
reflect disease stage and therefore serve as a valuable 
biomarker in patients with decompensated cirrhosis. 
This signature was assessed in terms of its capacity to 
1) discriminate between patients with diuretic-sensi-
tive and refractory ascites; 2) anticipate the develop-
ment of cardiac dysfunction in response to NSBBs; 
and 3) predict the HVPG response to NSBBs.
Materials and Methods
stuDy Design
Our study consisted of three steps: 1) identification 
of a novel miRNA signature in the secretome of cul-
tures of human hepatocytes; 2) analysis of the miRNA 
signature in serum samples from a well-characterized 
cohort of patients with decompensated cirrhosis and 
from age- and sex-matched healthy controls; and 3) 
correlation of serum levels of these miRNAs with 
clinical outcomes in patients with decompensated cir-
rhosis (Fig. 1).
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This was a collaborative translational project involv-
ing human samples. The study protocol adhered to the 
principles of the Declaration of Helsinki. The study´s 
first stage in which the miRNA signature was identi-
fied was conducted at the August Pi i Sunyer Biomedical 
Research Institute-Hospital Clinic of Barcelona, and its 
protocol was approved by this center´s Ethics Committee 
(HCB/2018/0028). The protocol for subsequent stages 
received approval from the Ethics Committee for Clinical 
Research of the Hospital Universitario Ramon y Cajal 
(institutional review board number 362/19; approval date 
April 1, 2019). All included subjects provided written 
informed consent authorizing the storage and research 
use of their biological samples.
iDentiFiCation oF a noVel 
miRna signatuRe in tHe 
seCRetome oF CultuRes oF 
Human HepatoCytes
Hepatocytes were isolated from explants of livers 
from patients with decompensated cirrhosis (n  =  9, all 
of alcoholic etiology) and livers from patients under-
going partial liver resection for hepatic metastases of 
Fig. 1. Study design. The study was developed in three steps: A) Identification of a novel miRNA signature in the secretome of cultures 
of human hepatocytes from cirrhotic and noncirrhotic livers. The heatmap represents the 20 most deregulated miRNAs (the top 10 up-
regulated and the top 10 down-regulated) detected after sequencing small EVs from cirrhotic and noncirrhotic hepatocyte secretome. 
The five miRNAs integrating the novel signature are those that presented a greater fold change and statistically significant difference. B) 
miRNA signature analysis in serum samples of patients with decompensated cirrhosis and age- and sex-matched healthy controls. The 
novel signature of five miRNAs identified in the previous step was measured in serum samples of patients with cirrhosis. C) Correlation of 
miRNAs in serum and clinical outcomes in patients with decompensated cirrhosis. miRNAs were measured in patients’ serum at baseline 
and 1 month after treatment with NSBBs. miRNAs levels were correlated with disease stage (diuretic-sensitive vs. refractory ascites), the 
cardiac systolic function measured by echocardiography, and the portal pressure response to NSBBs.
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colorectal cancer (n = 9) who had not received chemo-
therapy. The viability of samples from liver metastases 
was assessed by the Pathology Department to ensure 
that the isolated hepatocytes were not affected by their 
proximity to tumor tissue. For the isolation and culture 
of hepatocytes, we used validated protocols.(14) Cells 
were seeded on collagen-coated 150-cm2 Petri dishes at 
a density of 2 × 107 cells per dish and cultured (37°C, 
5% CO2) in Dulbecco’s modified Eagle’s medium F-12 
Ham supplemented with penicillin-streptomycin solu-
tion (1% volume [vol]/vol), L-glutamine (1% vol/vol), 
and exosome-depleted fetal bovine serum (2% vol/vol). 
After 24 hours of culture, the supernatant was collected, 
centrifuged at 2,000g for 10 minutes at room tempera-
ture, and filtered with 0.22-µm filters to remove apoptotic 
bodies. Subfractions enriched in small EVs generated by 
the hepatocytes, mainly exosomes, were obtained by sub-
sequent ultracentrifugations.(15,16) Small EV subfractions 
were routinely tested for purity and quality by nanopar-
ticle tracking analysis (NanoSight). The Bradford assay 
was used to determine protein concentration, and the 
EVs were stored at −80°C for further analysis. EV sam-
ples were pooled in groups of three for proper RNA iso-
lation and analysis. Total RNA was isolated (miRVANA 
Paris Kit; Ambion/Thermo Fisher Scientific) from 50 µg 
of EV preparation and 2 µL of 1 nM. Each sample was 
spiked with Caenorhabditis elegans miR-39-5p. The quan-
tity and profiles of the obtained RNAs were examined 
using Agilent RNA 6000 Pico Chips (#5067-1513; 
Agilent Technologies). Sequencing libraries were pre-
pared using NEXTflex Small RNA-Seq Kit v3 (#5132-
05; Bioo Scientific Corporation) following the protocol 
for NEXTflex Small RNA-Seq Kit v3 V16.06. Briefly, 
RNA samples were incubated for 2 minutes at 70°C, then 
3′ 4N adenylated adapter and ligase enzyme were added; 
ligation was conducted overnight at 20°C. After removal 
of excess 3′-adapter, 5′-adapter and ligase enzyme were 
added and the mix incubated at 20°C for 1  hour. The 
ligation product was used for reverse transcription with 
Moloney murine leukemia virus reverse transcriptase in a 
thermocycler for 30 minutes at 42°C and 10 minutes at 
90°C. Next, complementary DNA (cDNA) was enriched 
by polymerase chain reaction (PCR) cycling as follows: 
2 minutes at 95°C; 22-25 cycles of 20 seconds at 95°C, 
30 seconds at 60°C, and 15 seconds at 72°C; final elon-
gation for 2 minutes at 72°C; and the reaction stopped 
at 4°C. PCR products were resolved on 6% Novex 
Tris/borate/ethylene diamine tetraacetic acid polyacryl-
amide gel electrophoresis gels (#EC6265BOX; Thermo 
Fisher Scientific), and the band between 150 base pairs 
(bp) and 300 bp was cut out from the gel. The prod-
ucts were extracted from the polyacrylamide gel using 
an adapted protocol in which cDNA from gel slices was 
diluted in double-distilled H2O. Next, the libraries were 
analyzed quantitatively and qualitatively in an Agilent 
2100 Bioanalyzer using the Agilent High Sensitivity 
DNA Kit (#5067-4626; Agilent Technologies) and 
Qubit double-stranded DNA HS DNA Kit (#Q32854; 
Thermo Fisher Scientific). The libraries were single-read 
sequenced for 51 nucleotides in a HiSeq2500 System 
(Illumina) at the CIC bioGUNE genome analysis plat-
form. After sequencing, the raw data were processed to 
identify miRNAs differentially expressed among the 
established groups by univariate analysis according to 
the criteria that the fold change was at least 1.5 and P < 
0.05 (all microRNAs identified after sequencing are indi-
cated in Supporting Fig. S1). The differential expression 
of selected miRNAs was validated by specific TaqMan 
individual quantitative reverse-transcription (qRT)-PCR 
assays. All five miRNAs comprising the newly identified 
signature (miR-452-5p, miR-429, miR-885-5p, miR-
181b-5p, and miR-122-5p) were registered at the miR-
Base database (www.mirba se.org). RNA sequencing data 
are deposited and stored in Gene Expression Omnibus 
under accession number GSE15 0867.
analysis oF tHe miRna 
signatuRe in seRum samples 
FRom patients WitH 
DeCompensateD CiRRHosis 
anD HealtHy ContRols
The novel miRNA signature along with three miR-
NAs (miR-192-5p, miR-34a-5p, and miR-29a-5p) 
identified previously as biomarkers of chronic liver dis-
ease(17-19) were measured in serum samples from patients 
with decompensated cirrhosis and healthy individuals.
Serum samples from patients with decompen-
sated cirrhosis were from a registered collection 
(C.0005352, Collections Section of the Biobank 
Registry of Instituto de Salud Carlos III, Madrid, 
Spain) of a cohort of 36 patients with cirrhosis and 
ascites treated with an NSBB (propranolol) for pri-
mary prophylaxis of variceal bleeding. Serum sam-
ples were collected before and 4 weeks after starting 
treatment with NSBBs between April 2016 and 
December 2018, and miRNA assays were performed 
in April 2019. Serum samples were centrifuged at 
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2,000g for 15 minutes at 22°C, and the supernatants 
aliquoted and stored at −80°C until miRNA analysis.
Healthy individuals were those matched for sex and 
age with no history of liver disease. Serum samples 
(n = 36) from the local blood transfusion center were 
provided by the Hospital Universitario Ramon y Cajal-
Instituto Ramon y Cajal de Investigacion Biosanitaria 
(IRYCIS) (Registry of Biobanks of the Instituto de 
Salud Carlos III No. B.0000678) within the National 
Network of Biobanks (PT17/0015/0010). All samples 
were obtained with the approval of the corresponding 
ethics and scientific committees and processed fol-
lowing standard procedures. Serum was obtained by 
centrifugation at 1,100g for 10 minutes at 4°C, then 
aliquoted and immediately stored at −80°C.
For serum miRNA analysis, we first isolated total 
RNA from 200  μL of serum with the Plasma/Serum 
RNA Purification Mini Kit (#55000; Norgen Biotek, 
Thorold, Canada) according to the manufacturer´s pro-
tocol. Next, the expression of miRNAs was analyzed 
through amplification in individual qRT-PCR reactions 
using commercially available locked nucleic acid probes 
specific for each miRNA of interest (miRNA primer 
sets from Exiqon A/S, Vedbæk, Denmark). All reac-
tions were performed in triplicate with Light Cycler 480 
equipment (Roche) following the supplier´s guidelines. 
The relative expression of each miRNA was calculated 
using miR-103a-3p as the housekeeping gene to mini-
mize analytic variability and obtain a reliable and repro-
ducible result. This housekeeping gene showed the least 
variability among the tested normalizers recommended 
for serum by the supplier (Qiagen) (miR-103a-3p, miR-
191-5p, miR-30a, and miR-124-3p). miR-103a-3p was 
chosen for data normalization as it showed the lower SD 
between all samples tested. In fact, miR-103a-3p and 
miR-191-5p have been reported to be stable endoge-
nous reference genes in serum for data normalization.(20) 
miRNA levels are expressed according to the compar-
ative cycle threshold (Ct) method ∆Ct, where ∆Ct = 
average Cttested miRNA – average CtmiR-103a-3p (average Ct 
is the mean of the technical triplicate), which inversely 
correlates with the amount of miRNA in the serum.
CliniCal CHaRaCteRiZation 
anD stuDy oF patients WitH 
DeCompensateD CiRRHosis
A cohort of 36 patients with decompensated cir-
rhosis, 18 of whom had refractory ascites defined 
according to the International Club of Ascites,(21) 
was examined before and 4 weeks after start-
ing treatment with an NSBB (propranolol) as 
part of a prospective protocol (ClinicalTrials.gov 
NCT02163512).(7) Examinations included a com-
prehensive Doppler echocardiography study, hepatic 
and cardiopulmonary hemodynamic assessment, and 
blood tests. In brief, heart rate and mean arterial 
pressure were measured with an automatic sphyg-
momanometer; free and wedged hepatic venous 
pressures were obtained by placing a balloon cathe-
ter in the hepatic vein; cardiac output was measured 
by thermodilution using a Swan-Ganz catheter; and 
color Doppler M-mode images from the five-cham-
ber view were obtained by echocardiography. The 
HVPG was calculated as the difference between 
mean wedged and free hepatic pressures. Systemic 
vascular resistance was estimated according to the 
formula (mean arterial pressure – right atrial pres-
sure) × 80 / cardiac output. Hemodynamic response 
to NSBBs was defined as a decrease in HVPG by 
≥10% because this has been proposed as the best tar-
get to define a response in primary prophylaxis.(9,10) 
Cardiac systolic function was estimated by Doppler 
echocardiography using custom software through 
the ejection intraventricular pressure difference 
(EIVPD). This index accounts for the difference 
in pressure between the apex and the left ventricle 
outflow tract in the normal heart due to blood flow 
acceleration during early systole. The EIVPD is a 
robust loading-independent index closely related to 
the force of contractility of the left ventricle that 
has been proved highly reliable in decompensated 
cirrhosis.(7,22) Detailed information on the methods 
used for clinical measurements is provided as online 
Supporting Material.
BioinFoRmatiCs stuDies
The potential functional significance and inter-
actions of the miRNAs were assessed through bio-
informatics data mining. Functional enrichment 
analysis was performed on predicted target genes of the 
selected miRNAs using cluster Profiler software.(23) To 
assess interactions, we used the miRGate database and 
accepted those predictions with three or more compu-
tational validations or one experimental validation.(24) 
Bipartite networks were built using the selected miR-
NAs as source and regulated genes as targets.
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statistiCal analysis
The Shapiro-Wilk test and distribution plots were 
used to establish the normality of the data. Continuous 
variables provided as the median and interquartile 
range were compared through univariate analysis 
using a nonparametric test (Mann-Whitney U test). 
For paired continuous data, the Wilcoxon signed-
rank test was used. Categorical variables are provided 
as absolute and relative frequencies, and the Fisher´s 
exact test was used for intergroup comparisons. 
The expression of miRNAs was correlated with the 
response to NSBBs by calculating the Spearman cor-
relation coefficient. The area under the curve (AUC) 
was used to assess the diagnostic performance of the 
selected miRNAs. Optimal cutoffs of sensitivity and 
specificity were calculated for each miRNA based on 
the receiver operating characteristic curves. Statistical 
analysis was performed using Stata/IC 14.0. All tests 
were two-tailed. Significance was set at P < 0.05.
Results
iDentiFying an miRna 
signatuRe in tHe seCRetome 
oF pRimaRy Human 
HepatoCytes
We first analyzed the secretome of primary human 
hepatocytes isolated from tissue remnants of liver 
explants and partial hepatic resections from patients 
with cirrhosis and liver metastases, respectively. This 
involved examining the noncodifying RNA contents 
of small EVs present in the secretome. We identi-
fied a signature of five miRNAs (miR-452-5p, miR-
429, miR-885-5p, miR-181b-5p, and miR-122-5p) 
that were differentially expressed in the secretome of 
hepatocytes from livers with and without cirrhosis.
miRna signatuRe ValiDation 
in seRum samples oF patients  
WitH CiRRHosis anD ContRols
Our next step was to validate the identified miRNA 
signature in the serum of patients with decompen-
sated cirrhosis. As a control, we also checked whether 
three miRNAs (miR-192-5p, miR-34a-5p, and miR-
29a-5p) previously identified as biomarkers of chronic 
liver disease were differentially expressed in total 
circulating RNA isolated from patients and healthy 
controls.
Serum samples from 36 patients with cirrhosis 
with ascites (50% refractory ascites) and 36 age- and 
sex-matched healthy controls were tested for the 
expression of the novel miRNA signature. miRNAs 
could not be determined in 3 patients with cirrhosis 
as samples were collected in heparinized tubes caus-
ing qRT-PCR inhibition. These 3 patients and their 
corresponding controls were thus excluded from the 
study. The baseline characteristics of the study pop-
ulation (33 patients with cirrhosis, 81.8% men, mean 
age 58 years [range, 54-61], 16 with diuretic-sensitive 
ascites, and 17 with refractory ascites) are detailed in 
Table 1.









Age, years 55 (52-59) 59 (54-65) 0.4
Male sex 13 (81.2%) 14 (82.3%) 0.64
Etiology of cirrhosis 0.15
Alcohol 13 (81.2%) 10 (58.8%)
Viral 3 (18.8%) 7 (41.2%)
Child-Pugh score 0.15
B 13 (81.2%) 10 (58.8%)
C 3 (18.8%) 7 (41.2%)
MELD score 12 (10-16) 16 (13-17) 0.12
Baseline laboratory parameters
Bilirubin (mg/dL) 1.9 (1-3.5) 2.2 (1.3-3.6) 0.63
Albumin (g/dL) 3 (2.5-3.3) 2.9 (2.6-3.3) 0.97
INR 1.3 (1.3-1.5) 1.5 (1.3-1.6) 0.17
Creatinine (mg/dL) 0.7 (0.7-0.8) 0.9 (0.7-1) 0.08
eGFR (mL/minute/1.73 m2) 103 (84-120) 79 (58-87) 0.01
Cystatin C (mg/dL) 1.2 (1.1-1.2) 1.6 (1.2-2) 0.03
Sodium (mEq/L) 135 (133-137) 132 (131-134) 0.01
Baseline hemodynamic 
parameters
Mean arterial pressure  
(mm Hg)
91 (85-97) 80 (74-92) 0.006







HVPG (mm Hg) 21 (19-25) 23 (19-25) 0.81
EIVPD (mm Hg) 4.1 (3.2-5.4) 4.6 (2.9-5.8) 0.65
Quantitative variables are provided as median and interquartile 
range. Qualitative variables are provided as absolute values and 
percentages.
Abbreviations: eGFR, estimated glomerular filtration rate; INR, 
international normalized ratio; sec, seconds.
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Our validation study in serum samples of the 
miRNA signature confirmed different expression 
levels in patients versus controls of four of the five 
miRNAs comprising the signature and two of the 
three miRNAs assessed as controls. Compared to 
controls, patients with cirrhosis showed significantly 
(P  <  0.005) lower levels of miR-429, miR-885-5p, 
miR-181b-5p, miR-122-5p, miR-192-5p, and miR-
29a-5p (P  <  0.05) and similar levels of miR-452-5p 
and miR-34a-5p (Fig. 2). Of these differentially 
expressed markers, miR-29a-5p showed the highest 
AUC for the identification of cirrhosis (AUC, 0.88; 
95% confidence interval [CI], 0.8-0.95; sensitiv-
ity, 78.8%; specificity, 78.8% for cut-off point 1.53), 
as depicted in Supporting Fig. S2. Of note, miRNA 
serum levels did not correlate with the classic scores 
of liver function (Model for End-Stage Liver Disease 
[MELD], MELD-Na, and Child-Pugh), as detailed 
in Supporting Table S1.
seRum miRna signatuRe 
eXpRession anD CliniCal 
outComes in patients WitH 
DeCompensateD CiRRHosis
serum miRna expression in Refractory 
ascites
Baseline levels of miR-181b-5p were significantly 
higher in patients with refractory ascites than diuretic- 
sensitive ascites (P  =  0.008). miR-181b-5p levels 
showed an AUC of 0.77 (95% CI, 0.59-0.93; sensi-
tivity, 75%; specificity, 70.6% for cut-off point 6.57) 
to identify patients with refractory ascites, as depicted 
Fig. 2. miRNA serum expression in patients with cirrhosis and healthy controls. The vertical lines indicate the range, the middle 
horizontal line is the median, and the horizontal boundaries of the boxes represent the first and third quartile. miRNAs from the novel 
signature appear highlighted in the table.
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in Fig. 3A,B. The other miRNAs examined did not 
differ significantly in their levels between refrac-
tory and diuretic-sensitive ascites (Supporting Fig. 
S3). Levels of miR-181b-5p expression showed an 
inverse correlation with indicators of renal function 
(serum creatinine, ρ = −0.5, P = 0.002; and cystatin C, 
ρ = −0.44, P = 0.01). This correlation was restricted to 
patients with refractory ascites (creatinine, ρ  =  −0.6, 
P = 0.01 in refractory ascites vs. ρ = −0.26, P = 0.32 
in diuretic-sensitive ascites; cystatin C, ρ  =  −0.54, 
P = 0.02 in refractory ascites vs. ρ = −0.02, P = 0.92 
in diuretic-sensitive ascites), as detailed in Fig. 3C.
In the whole group of patients with ascites, serum 
levels of miR-452-5p and miR-885-5p correlated with 
severity of systemic vasodilation. Lower systemic vas-
cular resistance had lower serum levels of miR-452-5p 
and miR-885-5p (ρ = −0.46, P = 0.007; and ρ = −0.42, 
P = 0.01, respectively), as represented in Fig. 4.
serum miRna expression and 
Response to Beta-Blockade
Mean HVPG at baseline was 22 mm Hg,(19-25) 
with no significant differences between refractory and 
Fig. 3. Diuretic-sensitive versus refractory ascites. (A) miR-181b-5p serum expression in patients with diuretic-sensitive and refractory 
ascites. The vertical lines indicate the range, the middle horizontal line is the median, and the horizontal boundaries of the boxes represent 
the first and third quartile. (B) Receiver operator characteristic curve of miR-181b-5p to identify patients with refractory ascites. Each 
point on the ROC curve represents a different cutoff value for a sensitivity/specificity pair. (C) Correlation between miR-181b-5p and renal 
function parameters. Points represent individual patients. Abbreviation: AUROC, area under the receiver operator characteristic curve.
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diuretic-sensitive ascites (P  =  0.81). Baseline serum 
miRNAs levels showed no correlation with base-
line HVPG (Supporting Table S1). miRNA levels 
did not significantly change after NSBBs, as repre-
sented in Supporting Fig. S4. Seventeen patients 
(51.5%) showed a hemodynamic response to NSBBs 
defined as a drop in HVPG ≥ 10%. Baseline serum 
miR-452-5p and miR-429 levels were significantly 
lower (P  <  0.05) in responders than nonresponders 
to NSBBs (Fig. 5A). Levels of miR-181b-5p and 
miR-29a-5p showed a similar tendency, albeit non-
significant (P = 0.05 and P = 0.06, respectively), while 
other miRNAs did not differ significantly between 
responders and nonresponders (Supporting Fig. S5). 
Their AUC to identify a response to NSBBs was 0.77 
(95% CI, 0.59-0.95; sensitivity, 82.4%; specificity, 
75% for a 9.26 cutoff ) for miR-452-5p and also 0.77 
for miR-429 (95% CI, 0.61-0.94; sensitivity, 76.5%; 
specificity, 81.2% for a 10.2 cutoff ), as represented in 
Fig. 5B.
Treatment with NSBBs resulted in significantly 
reduced systolic cardiac function as estimated by 
EIVPD in patients with refractory ascites before 
NSBBs (mean, 4.6; 2.9-5.8 mm Hg) versus after 
NSBBs (mean, 3.3; 3-4.1 mmHg; P  =  0.005) but 
not in those with diuretic-sensitive ascites (P  =  0.3). 
Baseline miR-452-5p and miR-885-5p inversely cor-
related with impaired systolic function produced after 
NSBBs in patients with refractory ascites (ρ = −0.55, 
P  =  0.02; and ρ  =  −0.55, P  =  0.02, respectively), as 
shown in Fig. 6.
FunCtional signiFiCanCe oF 
miRnas
Our bioinformatics analysis was designed to assess 
the potential functional implications of the miRNAs 
examined here. As illustrated in Supporting Fig. S6, 
these miRNAs and their target genes play essential 
roles in several biological processes, mostly in cell 
response to hypoxia.
We found a functional relationship among the 
validated miRNAs based on shared target prediction, 
which is represented as a network in Supporting 
Fig. S7. In this relationship, miR-452-5p, miR-
429, miR-181b-5p, miR-122-5p, miR-192-5p, and 
Fig. 5. Hemodynamic response to NSBBs. (A) miR-452-5p and miR-429 serum expression in patients with and without hemodynamic 
response to NSBBs. The vertical lines indicate the range, and the horizontal lines are the median and first and third quartile. Points represent 
individual patients. (B) Receiver operator characteristic curves of miR-452-5p and miR-429 to predict hemodynamic response to NSBBs. 
Each point on the ROC curve represents a different cutoff value for a sensitivity/specificity pair. Abbreviation: AUROC, area under the 
receiver operator characteristic curve.
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miR-34a-5p control the expression of common tar-
gets that might cooperate to promote cell response; 
miR-429, miR-181b-5p, and miR-34a-5p control 
the expression of a common target, B-cell lym-
phoma 2 (BCL2); and miR-429, miR-181b-5p, and 
miR-192-5p seem to be related through the gene 
X-linked inhibitor of apoptosis protein (XIAP). 
Additionally, BCL2 and XIAP are genes involved in 
the apoptotic process.
Discussion
To the best of our knowledge, this is the first 
study to focus on circulating miRNAs as potential 
biomarkers of disease stage in decompensated cir-
rhosis. Our findings reveal the differential expres-
sion of a novel miRNA signature in the serum of 
patients with refractory ascites. Our study also shows 
the capacity of this signature to distinguish patients 
with decompensated cirrhosis with severe peripheral 
vasodilation, who are more prone to develop signif-
icant cardiac impairment after NSBBs, as well as 
those more likely to respond to NSBBs in terms of 
HVPG reduction. In addition to the novel signa-
ture, we also examined the behavior of three miR-
NAs that have been previously related to chronic 
liver disease. We confirmed that two of these three 
miRNAs were able to differentiate patients with cir-
rhosis from healthy controls, but they did not serve 
to characterize decompensated cirrhosis or to pre-
dict the response to beta-blockade.
The translational design of our study allowed 
for the identification of a signature of circulating 
miRNAs. We hypothesized that serum miRNAs 
with potential diagnostic value as biomarkers in 
decompensated cirrhosis might include, among oth-
ers, miRNAs previously identified in the secretome 
of hepatocytes from the cirrhotic livers of patients 
with decompensated disease. For this purpose, we 
first identified miRNAs differentially expressed in 
the EVs of the supernatant of cultures of human 
hepatocytes from cirrhotic and noncirrhotic livers. 
We postulated that the miRNA signature charac-
terized in vitro could be a marker of clinical out-
comes in decompensated cirrhosis. It is conceivable 
that the miRNA content of EVs is specific of its 
cell source and reflects the physiological/pathologi-
cal state of the corresponding tissue.(25) In keeping 
with this approach and for the sake of methodolog-
ical simplicity, we opted for the analysis of miRNA 
in serum instead of isolated serum EVs. Our results 
confirmed our working hypothesis as the miRNA 
signature first identified in EVs and thereafter in 
serum was found to correlate with outcomes in 
patients with decompensated cirrhosis.
Six of the miRNAs examined (miR-429, miR-
885-5p, miR-181b-5p, miR-122-5p, miR-192-5p, 
and miR-29a-5p) were differentially expressed in our 
cohort of patients with decompensated cirrhosis com-
pared to controls. The best diagnostic accuracy for 
cirrhosis was shown by miR-29a-5p, which has been 
reported to be down-regulated in patients with cir-
rhosis.(19) The five other miRNAs appearing in sig-
nificantly lower levels in the serum of patients with 
cirrhosis were miR-429, which has not been studied 
in liver disease; and miR-122-5p, miR-885-5p, miR-
181b-5p, and miR-192-5p, for which higher serum 
levels have been detected in patients with chronic 
liver disease compared to controls. The presence of 
miRNAs has been explored in several liver diseases, 
such as viral hepatitis, nonalcoholic fatty liver disease 
Fig. 6. Correlation between miR-452-5p and miR-885-5p with the fall of systolic function after NSBB.
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(NAFLD), or hepatocellular carcinoma.(26-28) In these 
studies, however, patients with decompensated cir-
rhosis were barely represented. This could explain the 
discrepancies (up-regulation vs. down-regulation) in 
the levels of circulating miRNAs between our study 
and those of others. In agreement with our findings, 
reduced serum levels of miR-122, the most abundant 
miRNA in the liver, and of miR-885-5p have been 
reported in patients with decompensated compared 
to those with compensated cirrhosis.(29-31) Such lower 
serum levels of these miRNAs in patients with more 
advanced disease may be secondary to their reduced 
secretion due to a loss of functional hepatocytes rather 
than to their increased release from injured hepato-
cytes seen in earlier stages of liver diseases.
A noteworthy finding of our study was the ability 
of miR-181b-5p to identify patients with refractory 
ascites. Whereas the role of miRNAs as biomark-
ers in chronic liver disease has focused on diagno-
sis and NAFLD stratification,(32) ours is the first 
study to explore their predictive value specifically 
in decompensated cirrhosis. Refractory ascites is 
clinically defined by expert consensus as a stage of 
further decompensation of cirrhosis characterized 
by severe circulatory dysfunction and limited car-
diac reserve.(7,21) Classical scores of liver function 
do not reflect the severity of circulatory dysfunction 
or the labile nature of renal function these patients 
feature.(7) Indeed, while there were no differences 
in Child-Pugh and MELD between patients with 
diuretic-sensitive and refractory ascites in our 
cohort, remarkably, miR-181b-5p was up-regulated 
in the serum of patients with refractory ascites and 
showed an AUC of 0.77 to identify this patient 
subset. Moreover, serum levels of this miRNA were 
correlated with the degree of renal impairment. The 
marked differences in serum miRNA levels between 
refractory and diuretic-sensitive ascites support the 
notion of a distinctive pathophysiological back-
ground underlying the classical clinical differentia-
tion of the two substages of decompensated cirrhosis, 
which are accurately identified by the miRNA sig-
nature. Further, we have also observed that a greater 
serum expression of miR-452-5p and miR-885-5p 
shows a greater severity of peripheral vasodilation, 
i.e., the ability of these miRNA to identify those 
patients with the more severe circulatory dysfunc-
tion. Interestingly, because the severity of peripheral 
vasodilation and the reduction in systolic function 
induced by beta-blockade are closely related, expres-
sion levels of miR-452-5p and miR-885-5p were 
also linked to the declining systolic function after 
NSBBs.(7) Taken together, our results provide proof-
of-concept evidence of the value of miRNA profil-
ing to stratify decompensated cirrhosis.
Our study also explores whether miRNAs are able 
to predict the HVPG response to NSBBs. NSBBs 
prevent primary and recurrent variceal bleeding and 
improve survival in patients with compensated and 
decompensated cirrhosis.(9-12) The benefits of NSBBs 
for clinical outcomes are closely linked to the fall in 
HVPG produced in response to beta-blockade, which 
is largely variable among patients and can only be 
addressed by its measurement.(11) Thus, noninvasive 
biomarkers, i.e., differential expression of miRNAs, 
could represent an innovative theranostic approach to 
identify this HVPG response to NSBBs. We found 
that HVPG responders to NSBBs had lower baseline 
serum levels of miR-452-5p and miR-429, suggesting 
their potential clinical utility as prognostic of the portal 
pressure response to NSBBs. Similarly, other miRNAs, 
such as miR-19a, miR-101, and let-7e, which regulate 
β1-adrenergic receptors, and other beta-blocker phar-
macodynamics-related genes, have been associated 
with the antihypertensive response to beta-blockers.(33)
Elucidating the biological functions of individual 
miRNAs is complex as they may influence several mes-
senger RNAs and more than one miRNA can regulate 
one messenger RNA. The search of biomarkers is fur-
ther complicated by the fact that the underlying mech-
anisms of the clinical processes addressed in this study, 
i.e., refractory ascites, HVPG response to NSBBs, 
are multifactorial. Most of the miRNAs shown here 
to correlate with clinical outcomes in decompensated 
cirrhosis have also been associated with disorders of 
renal function and cardiocirculatory dysfunction, all 
of which are involved in chronic liver disease progres-
sion. In this context, miR-181b-5p, which served to 
identify the most severe stage of cirrhosis (refractory 
ascites), has been related to proliferation and activa-
tion of hepatic stellate cells(34,35) and cardiovascular 
remodeling.(36-38) Accordingly, miR-181b-5p has been 
proposed as a marker of fibrosis severity in chronic 
liver disease,(39) disease progression in chronic hepatitis 
B,(40) and cardiac dysfunction in diabetic cardiomyop-
athy.(38) However, it is likely that the role of miRNAs 
in modifying biological processes involves more their 
cooperation to regulate gene networks and repress one 
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or more target genes than individual actions. Our anal-
ysis of the functions possibly overrepresented in the set 
of genes regulated by our novel signature revealed their 
involvement largely in the response to hypoxia by the 
control of critical genes involved in the apoptotic pro-
cess, such as BCL2 or XIAP. Hypoxia plays a pivotal 
role in the natural history of cirrhosis as it stimulates 
angiogenesis, inhibits cell proliferation factors, and pro-
motes fibrogenesis, contributing to progressive portal 
hypertension and hyperdynamic circulation.(41)
We acknowledge certain limitations of our study. 
First, its exploratory nature and limited sample 
size means its results need to be validated in larger 
cohorts. Second, the miRNA signature identified as 
representative of changes in the secretome of the 
hepatocytes from cirrhotic livers was identified and 
sequenced from small EVs, whereas we analyzed 
individual miRNAs in total serum. We ruled out our 
initial plan to only isolate small EVs in the serum 
samples because there is no efficient method to 
obtain these vesicles from blood, especially in a large 
number of samples already collected and aliquoted 
in small volumes. To avoid losing information, we 
move toward a more reproducible and pragmatic 
approach that does not require sophisticated equip-
ment to facilitate clinical use. Thus, using a com-
mercial kit, we isolated the whole RNA content 
of the sample, including that associated with small 
EVs and exosomes, and then analyzed the individual 
miRNAs of the signature. It could also be argued 
that miRNAs are produced by multiple cell types 
and miRNAs in primary cell cultures may differ 
from those in circulation. However, our study does 
not attempt to identify the cell source of the miR-
NAs but rather their validity as biomarkers in a 
specific pathological context, namely, for the non-
invasive identification of patients in whom NSBBs 
could be futile or harmful. Finally, validation of the 
miRNA signature should include cirrhosis etiologies 
other than alcohol because the latter was the cause 
of cirrhosis in the livers from which primary human 
hepatocytes were obtained as well as the most fre-
quent etiology of cirrhosis in our patient series.
In conclusion, this study identifies a novel circu-
lating miRNA signature that allows for the molecu-
lar characterization of patients with decompensated 
cirrhosis. The up-regulation of miRNA 181b-5p was 
identified as a feature of refractory ascites. In addition, 
the down-regulation of miRNA 452-5p and 885-5p 
was found to reflect the magnitude of hemodynamic 
impairment that occurs in these patients as these 
miRNAs identify patients with severe circulatory dys-
function who are more likely to develop systolic car-
diac impairment in response to beta-blockade. Finally, 
down-regulation of miR-452-5p and miR-429 iden-
tified patients more likely to have a significant reduc-
tion in portal pressure when treated with NSBBs. The 
present proof-of-concept study indicates that miRNAs 
are distinctive biomarkers of advanced decompensated 
cirrhosis and of relevant clinical outcomes, including 
the patient response to treatment with NSBBs.
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